BioCryst Pharmaceuticals Inc
ORLADEYO
hereditary angioedema
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on ORLADEYO for hereditary angioedema is expected Date TBD.
Primary source
· SEC 8-K
verified 15h ago
“Received FDA approval for ORLADEYO oral pellets for patients with HAE Aged 2 to <12 Years”